AAAAAA
Results:
1-23
|
Results: 23
Authors:
Linden, PK
Moellering, RC
Wood, CA
Rehm, SJ
Flaherty, J
Bompart, F
Talbot, GH
Citation: Pk. Linden et al., Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin, CLIN INF D, 33(11), 2001, pp. 1816-1823
Authors:
Talbot, GH
Kennedy, DW
Scheld, WM
Granito, K
Citation: Gh. Talbot et al., Rigid nasal endoscopy versus sinus puncture and aspiration for microbiologic documentation of acute bacterial maxillary sinusitis, CLIN INF D, 33(10), 2001, pp. 1668-1675
Authors:
Rehm, SJ
Graham, DR
Srinath, L
Prokocimer, P
Richard, MP
Talbot, GH
Citation: Sj. Rehm et al., Successful administration of quinupristin/dalfopristin in the outpatient setting, J ANTIMICRO, 47(5), 2001, pp. 639-645
Authors:
Linden, PK
Bompart, F
Gray, S
Talbot, GH
Citation: Pk. Linden et al., Hyperbilirubinemia during quinupristin-dalfopristin therapy in liver transplant recipients: Correlation with available liver biopsy results, PHARMACOTHE, 21(6), 2001, pp. 661-668
Authors:
Moellering, RC
Linden, PK
Reinhardt, J
Blumberg, EA
Bompart, F
Talbot, GH
Citation: Rc. Moellering et al., The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium (Reprinted from The Journal Antimicrobial Chemotherapy, vol 44, pg 251-261, 1999), FORMULARY, 35, 2000, pp. S25-S35
Authors:
Garrison, N
Spector, S
Buffington, D
Stafford, C
Granito, K
Zhang, H
Talbot, GH
Citation: N. Garrison et al., Sparfloxacin for the treatment of acute bacterial maxillary sinusitis documented by sinus puncture, ANN ALLER A, 84(1), 2000, pp. 63-71
Authors:
Dowzicky, M
Talbot, GH
Feger, C
Prokocimer, P
Etienne, J
Leclercq, R
Citation: M. Dowzicky et al., Characterization of isolates associated with emerging resistance to quinupristin/dalfopristin (Synercid (R)) during a worldwide clinical program, DIAG MICR I, 37(1), 2000, pp. 57-62
Authors:
Drew, RH
Perfect, JR
Srinath, L
Kurkimilis, E
Dowzicky, M
Talbot, GH
Citation: Rh. Drew et al., Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy, J ANTIMICRO, 46(5), 2000, pp. 775-784
Authors:
Rubinstein, E
Prokocimer, P
Talbot, GH
Citation: E. Rubinstein et al., Safety and tolerability of quinupristin/dalfopristin: administration guidelines, J ANTIMICRO, 44, 1999, pp. 37-46
Authors:
Moellering, RC
Linden, PK
Reinhardt, J
Blumberg, EA
Bompart, F
Talbot, GH
Citation: Rc. Moellering et al., The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium, J ANTIMICRO, 44(2), 1999, pp. 251-261
Authors:
Morganroth, J
Hunt, T
Dorr, MB
Magner, D
Talbot, GH
Citation: J. Morganroth et al., The effect of terfenadine on the cardiac pharmacodynamics of sparfloxacin, CLIN THER, 21(9), 1999, pp. 1514-1524
Authors:
Morganroth, J
Hunt, T
Dorr, MB
Magner, D
Talbot, GH
Citation: J. Morganroth et al., The cardiac pharmacodynamics of therapeutic doses of sparfloxacin, CLIN THER, 21(7), 1999, pp. 1171-1181
Authors:
Lipsky, BA
Unowsky, J
Zhang, H
Townsend, L
Talbot, GH
Citation: Ba. Lipsky et al., Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: Sparfloxacin versus clarithromycin, CLIN THER, 21(6), 1999, pp. 954-965
Authors:
Henry, DC
Nenad, RC
Irvani, A
Tice, AD
Mansfield, DL
Magner, DJ
Dorr, MB
Talbot, GH
Citation: Dc. Henry et al., Comparison of sparfloxacin and ciprofloxacin in the treatment of community-acquired acute uncomplicated urinary tract infection in women, CLIN THER, 21(6), 1999, pp. 966-981
Authors:
Johnson, RD
Dorr, MB
Hunt, TL
Jensen, BK
Talbot, GH
Citation: Rd. Johnson et al., Effects of food on the pharmacokinetics of sparfloxacin, CLIN THER, 21(6), 1999, pp. 982-991
Authors:
Dowzicky, M
Nadler, H
Dorr, MB
Acusta, A
Talbot, GH
Citation: M. Dowzicky et al., Comparison of the in vitro activity of and pathogen responses to sparfloxacin with those of other agents in the treatment of respiratory tract, urinary tract, and skin and skin-structure infections, CLIN THER, 21(5), 1999, pp. 790-805
Authors:
Morganroth, J
Talbot, GH
Dorr, MB
Johnson, RD
Geary, W
Magner, D
Citation: J. Morganroth et al., Effect of single ascending, supratherapeutic doses of sparfloxacin on cardiac repolarization (QT(c) interval), CLIN THER, 21(5), 1999, pp. 818-828
Authors:
Lipsky, BA
Miller, B
Schwartz, R
Henry, DC
Nolan, T
McCabe, A
Magner, DJ
Talbot, GH
Citation: Ba. Lipsky et al., Sparfloxacin versus ciprofloxacin for the treatment of community-acquired,complicated skin and skin-structure infections, CLIN THER, 21(4), 1999, pp. 675-690
Authors:
Henry, DC
Moller, DJ
Adelglass, J
Scheld, WM
Jablonski, CK
Zhang, H
Talbot, GH
Citation: Dc. Henry et al., Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis, CLIN THER, 21(2), 1999, pp. 340-352
Authors:
Johnson, RD
Dorr, MB
Hunt, TL
Conway, S
Talbot, GH
Citation: Rd. Johnson et al., Pharmacokinetic interaction of sparfloxacin and digoxin, CLIN THER, 21(2), 1999, pp. 368-379
Authors:
Ramirez, J
Unowsky, J
Talbot, GH
Zhang, H
Townsend, L
Citation: J. Ramirez et al., Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia, CLIN THER, 21(1), 1999, pp. 103-117
Authors:
Lipsky, BA
Dorr, MB
Magner, DJ
Talbot, GH
Citation: Ba. Lipsky et al., Safety profile of sparfloxacin, a new fluoroquinolone antibiotic, CLIN THER, 21(1), 1999, pp. 148-159
Authors:
Johnson, RD
Dorr, MB
Talbot, GH
Caille, G
Citation: Rd. Johnson et al., Effect of Maalox on the oral absorption of sparfloxacin, CLIN THER, 20(6), 1998, pp. 1149-1158
Risultati:
1-23
|